GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Matinas BioPharma Holdings Inc (AMEX:MTNB) » Definitions » Cash Flow from Investing

Matinas BioPharma Holdings (Matinas BioPharma Holdings) Cash Flow from Investing : $12.24 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Matinas BioPharma Holdings Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Matinas BioPharma Holdings spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $2.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Matinas BioPharma Holdings gained $2.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Matinas BioPharma Holdings Cash Flow from Investing Historical Data

The historical data trend for Matinas BioPharma Holdings's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Matinas BioPharma Holdings Cash Flow from Investing Chart

Matinas BioPharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.01 -40.67 16.77 4.88 13.24

Matinas BioPharma Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 6.20 1.08 2.96 2.00

Matinas BioPharma Holdings Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Matinas BioPharma Holdings's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Matinas BioPharma Holdings's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Matinas BioPharma Holdings  (AMEX:MTNB) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Matinas BioPharma Holdings's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Matinas BioPharma Holdings spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Matinas BioPharma Holdings's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Matinas BioPharma Holdings gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Matinas BioPharma Holdings's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Matinas BioPharma Holdings spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Matinas BioPharma Holdings's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Matinas BioPharma Holdings gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Matinas BioPharma Holdings's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Matinas BioPharma Holdings spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Matinas BioPharma Holdings's sale of investment for the three months ended in Mar. 2024 was $2.00 Mil. It means Matinas BioPharma Holdings gained $2.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Matinas BioPharma Holdings's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Matinas BioPharma Holdings paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Matinas BioPharma Holdings's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Matinas BioPharma Holdings paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Matinas BioPharma Holdings's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Matinas BioPharma Holdings paid $0.00 Mil for other investing activities.


Matinas BioPharma Holdings Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Matinas BioPharma Holdings's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Matinas BioPharma Holdings (Matinas BioPharma Holdings) Business Description

Traded in Other Exchanges
Address
1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.
Executives
Liu Hui officer: Chief Technology Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Thomas Hoover officer: Chief Business Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Kathryn Penkus Corzo director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Natasha Giordano director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Patrick G Lepore director 17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Jerome D Jabbour director, officer: Chief Executive Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Keith A Kucinski officer: Chief Financial Officer C/O MATINAS BIOPHARMA HOLDINGS INC., 1545 RT. 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Herbert J Conrad director C/O ARBUTUS BIOPHARMA CORP., 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Ferguson James J. Iii officer: Chief Medical Officer C/O MATINAS BIOPHARMA HOLDINGS INC., 1545 RT. 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Theresa Matkovits officer: Chief Development Officer C/O ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
Gary Gaglione officer: Chief Financial Officer C/O MATINAS BIOPHARMA HOLDINGS, 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Matthew Wikler director VIROPHARMA INCORP, 405 EAGLEVIEW BLVD, EXTON PA 19341
Raphael J Mannino officer: Chief Scientific Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921